"White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients

HIV Clinical Trials

Volumn 9, Issue 4, 2008, Pages 238-246

  Podsadecki, Thomas J ^a   Vrijens, Bernard C ^b   Tousset, Eric P ^b   Rode, Richard A ^a   Hanna, George J ^a  

^a ABBOTT LABORATORIES   (United States)

^b Pharmionic Systems   (Belgium)

Author keywords

Adherence; Antiretroviral therapy; Clinical trials; Lopinavir ritonavir; White coat compliance

Indexed keywords

EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA; AUSTRALIA; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; EUROPE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; NORTH AMERICA; PATIENT COMPLIANCE; PHOSPHONIC ACIDS; PYRIMIDINONES; RITONAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 51749109539     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0904-238     Document Type: Article

References (22)

1. Feinstein, AR. On white-coat effects and the electronic monitoring of compliance. Arch Int Med. 1990;150:1377-1378.
2. Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol. 1986;101:515-530.
3. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Int Med. 1990;150:1509-1510.
4. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
5. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses. 2002;18:825-834.
6. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2007. Available at: http://aidsinfo.nih.gov/guidelines. Accessed December 26, 2007.
7. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 Recommendations of the International AIDS Society-USA Panel. JAMA. 2006;296:827-843.
8. British HIV Association (BHIVA). Guidelines for the treatment of HIV disease with antiretroviral therapy. Update 2006. Available at: http://bhiva.org/. Accessed December 26, 2007.
9. French treatment guidelines. Prise en charge thérapeutique des personnes infectées par le VIH, recommendations du groupe d'experts. Misistére de l'emploi et de la solidarité. Rapport 2004. Available at: http://lesrapports.ladocumentationfrancaise.fr/BRP/064000613/0000.pdf. Accessed December 26, 2007.
10. Bertz R, Lam W, Brun S, et al. Multiple-dose pharmacokinetics (PK) of LPWritonavir (LPWr) in HIV+ subjects. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29 1999; San Francisco, California. Abstract 0327.
11. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:350-359.
12. Kaletra. US prescribing information. Available at: http://www.rxabbott.com/pdf/kaletratabpi.pdf. Accessed December 26, 2007.
13. Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006;43:153-160.
14. Molina J-M, Podsadecki TJ, Johnson MA, et al. A lopinavir/ ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Human Retroviruses. 2007;23:1505-1514.
15. Yeh V, Barros C, Easterbrook P, et al. Virologic response to a once-daily lopinavir/ritonavir (LPWr) based regimen in ARV-naïve patients is not associated with trough lopinavir concentrations or baseline HIV RNA and CD4 count. Poster presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 2004; Washington, DC. Poster H-570.
16. Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments. Control Clin Trials. 1997;18:187-203.
17. Vrijens B, Tousset E, Rode R, et al. Successful projection of the time course of drug concentration in plasma during a 1 -year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol. 2005;45:461-467.
18. Murray M, Wu J, Tu W. Treatment adherence agreement among concurrently administered medication. Presented at: European Symposium on PAtient COMpliance and Persistence (ESPACOMP); 2007; Lyon, France.
19. Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet. 1992;22:238-246.
20. Girard P, Sheiner LB, Kastrissios H, Blaschke TF. Do we need full compliance data for population pharmacokinetics analysis? J Pharmacokinet Biopharm. 1996;24:265-282.
21. Vrijens B, Goetghebeur E. The impact of compliance in pharmacokinetic studies. Stat Meth Med Res. 1999;8:247-262.
22. Chiu Y-L, King MS, Li J, et al. Trough lopinavir concentrations do not predict virologic response to lopinavir/ritonavir-based three-drug regimens in antiretroviral-naïve patients. Poster presented at: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; April 16-18 2007; Budapest, Hungary. Poster 38.